Advantage Investment Management’s Trinity Biotech TRIB Stock Holding History

Advantage Investment Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-60	Closed	-$2K	–	1076
2017 Q3	$2K	Hold	60	–	–	﹤0.01%	957
2017 Q2	$2K	Hold	60	–	–	﹤0.01%	985
2017 Q1	$2K	Hold	60	–	–	﹤0.01%	914
2016 Q4	$2K	Hold	60	–	–	﹤0.01%	867
2016 Q3	$4K	Hold	60	–	–	﹤0.01%	770
2016 Q2	$3K	Hold	60	–	–	﹤0.01%	760
2016 Q1	$4K	Hold	60	–	–	﹤0.01%	717
2015 Q4	$4K	Hold	60	–	–	﹤0.01%	724
2015 Q3	$3K	Hold	60	–	–	﹤0.01%	725
2015 Q2	$5K	Hold	60	–	–	﹤0.01%	702
2015 Q1	$6K	Hold	60	–	–	﹤0.01%	672
2014 Q4	$5K	Buy	+60	New	+$5.17K	﹤0.01%	624

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

Advantage Investment Management's TRIB Position: Q4 2017 in Review

Advantage Investment Management sold out of Trinity Biotech (TRIB) in Q4 2017, closing a stake of 60 shares — an estimated $2K sold.

Advantage Investment Management first reported a position in TRIB in Q4 2014 and held it in 12 quarters. The position peaked at $6K in Q1 2015. 48 funds tracked by Wall St. Rank hold TRIB as of Q4 2017.

Advantage Investment Management reported no remaining Trinity Biotech position as of Q4 2017 after selling out during the quarter.
Advantage Investment Management sold 60 Trinity Biotech shares in Q4 2017, an estimated $2K.
Advantage Investment Management first reported a position in Trinity Biotech in Q4 2014 and held it in 12 quarters.
Advantage Investment Management's Trinity Biotech position peaked at $6K in Q1 2015.
48 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2017.

Based on Advantage Investment Management's 13F filing for Q4 2017, filed 12 Feb 2018.